Scinvivo

Executive Summary

Scinvivo is a Dutch medical technology company developing a next-generation in vivo imaging platform for cancer diagnostics, with an initial focus on bladder cancer. The platform provides real-time, ultra-high-resolution visualization of tissue anatomy during endoscopic procedures, enabling earlier and more accurate cancer detection and staging. This technology aims to improve patient outcomes by reducing unnecessary surgeries and enabling timely intervention. Founded in 2009 and based in Leiden, the company operates in the oncology and drug delivery sectors, leveraging advanced imaging to address critical unmet needs in urologic oncology. Currently private with no disclosed funding or valuation, Scinvivo is poised to disrupt the standard of care for bladder cancer diagnosis, which largely relies on white-light cystoscopy with limited sensitivity.

Upcoming Catalysts (preview)

• Q3 2026CE Mark approval for bladder cancer imaging system60% success
• Q4 2026Publication of pivotal clinical trial results demonstrating improved detection rates versus standard cystoscopy50% success
• Q2 2026Partnership with a major urology device distributor for European commercialization40% success